V
Vascular Graft Solutions
Develops innovative solutions to improve the outcome of bypass surgery and patients’ quality of life
About Vascular Graft Solutions
Vascular Graft Solutions (VGS), established in 2009, focuses on improving coronary revascularization procedures through innovative technologies. Operating in the medical device industry, VGS primarily serves cardiac surgeons and healthcare providers involved in coronary artery bypass grafting (CABG). The company aims to enhance both short and long-term outcomes of CABG, a widely performed cardiac surgery, by providing external support for vein grafts. VGS's business model revolves around the development, clinical validation, and commercialization of its patented devices, which are FDA cleared and CE marked for sale in various regions including the US, Europe, Australia, Israel, and Mexico. Revenue is generated through the sale of these medical devices to hospitals and healthcare facilities. VGS's mission is to advance the standard of care in coronary bypass surgery, focusing on improving patient quality of life and reducing the economic burden on healthcare systems.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 71.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Surgery, Cardiology and cardiovascular, Patient Care, Spinout, Hospital, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Vascular Graft Solutions.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | May 2024 | $12M | $48M | Undisclosed | — |
| SERIES C✓Equity / VC | Jan 2022 | $12M | $48M | Undisclosed | — |
Growth signals
Latest recorded traffic for Vascular Graft Solutions is 400 monthly website visits, down 57.9% over the last three months. Vascular Graft Solutions's team grew 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Champel Capital
Series B and later1 investor entered at this stage
Broadview Ventures
Other known investors6 additional known investors
Tel Aviv University- APAkilia Partners
- MVMedison Ventures
Pontifax Funds
RAD BioMed
Tal Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vascular Graft Solutions on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vascular Graft Solutions’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.